Lupus Erythematosus, Systemic: all 1,222 studies
Page 3 of 13. Open to participants first (399), then studies with results posted, then the rest; newest registration first within each.
- Mesenchymal Stem Cells Infusion in Patients With Autoimmune DiseasesEnrolling by invitationNCT06888973Phase 1/2
- Safety Study of CC312 in Autoimmune Disease PatientsRecruitingNCT06888960Early Phase 1
- Chinese Rheumatism Biobank(CRB)RecruitingNCT06887517
- Clinical Study Evaluating the Safety and Efficacy of IC19 CAR-T Cell Therapy for Refractory Systemic Lupus ErythematosusNot yet recruitingNCT06886919Early Phase 1
- Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus ErythematosusRecruitingNCT06881290Phase 1
- Dose Response of Exercise for Arthritis ManagementRecruitingNCT06880653Not applicable
- A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132RecruitingNCT06875960Phase 4
- Assessment of Blood Indices in Systemic Lupus ErythematosusNot yet recruitingNCT06872086
- Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)Not yet recruitingNCT06859931Phase 2
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus ErythematosusRecruitingNCT06857214Phase 1
- Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus ErythematosusNot yet recruitingNCT06852573Phase 1
- Fibroblast Growth Factor 21 in Systemic Lupus ErythematosusNot yet recruitingNCT06842810
- Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory DiseasesRecruitingNCT06842316
- A Study of SCTB35 in Patients with Systemic Lupus ErythematosusRecruitingNCT06841042Phase 1/2
- CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusRecruitingNCT06839976Phase 1/2
- CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)RecruitingNCT06822881Phase 1
- CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness RegistryRecruitingNCT06804057
- Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）RecruitingNCT06801119Phase 1
- The Anifrolumab PRIM ProgramRecruitingNCT06795893
- BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesRecruitingNCT06794008Phase 2
- Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)Not yet recruitingNCT06791772Phase 2
- Blinatumomab in Refractory Active Childhood Systemic Lupus ErythematosusRecruitingNCT06789107Phase 1
- Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related FatigueNot yet recruitingNCT06784076
- Biomarkers in Inflammatory Rheumatic Diseases DiagnosisRecruitingNCT06778343
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) PatientsRecruitingNCT06737380Phase 1
- Assessment of Hematologic Indices in Juvenile Lupus Erythematosus Patients:Correlation With Disease Activity and Chronic Organ Damage in These PatientsRecruitingNCT06718283
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical ResearchRecruitingNCT06711146Early Phase 1
- Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT06710717Phase 1
- US Zamto-cel Autoimmune DiseasesRecruitingNCT06708845Phase 1
- A Study of SYS6020 Injection in Refractory Active Systemic Lupus ErythematosusNot yet recruitingNCT06694298Phase 1
- Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus ErythematosusRecruitingNCT06691152Phase 1
- Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune DiseasesRecruitingNCT06685042Phase 1/2
- NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus NephritisRecruitingNCT06676631Phase 1
- JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)RecruitingNCT06675422Phase 1/2
- Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersRecruitingNCT06659029
- Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.RecruitingNCT06657703Phase 1
- A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic DiseasesRecruitingNCT06647069Phase 1
- Different Aspects and Etiologies of Gastointestinal Bleeding in Patients With Systemic Lupus ErythematosusNot yet recruitingNCT06641427
- A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE ParticipantsRecruitingNCT06625671Phase 1/2
- Safety of Administering Isoniazid to SLE Patients to Prevent TBRecruitingNCT06618573Phase 2/3
- A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusRecruitingNCT06617325Phase 3
- Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune DiseasesRecruitingNCT06614270Not applicable
- A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusRecruitingNCT06613360Phase 1
- Association Between Neuropathy and Some Autoantibodies in Systemic Lupus Erythematosus (SLE) PatientsNot yet recruitingNCT06610422
- Studying Non Alcoholic Fatty Liver Disease and Liver Fibrosis Among Systemic Lupus Erythematosus Patients At Assiut University HospitalNot yet recruitingNCT06601361
- Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersRecruitingNCT06594068Phase 4
- ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUSRecruitingNCT06593041
- Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLERecruitingNCT06586710Not applicable
- Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus ErythematosusRecruitingNCT06585514Phase 1/2
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.RecruitingNCT06581562Phase 1
- A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD ParticipantsRecruitingNCT06576271Phase 1
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesRecruitingNCT06570798Phase 2
- JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune DiseasesNot yet recruitingNCT06567080Phase 1
- Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRURecruitingNCT06551389
- Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune DiseasesRecruitingNCT06548607Early Phase 1
- Integration of Remote Monitoring in the Management of Chronic Immunosuppressive TherapyRecruitingNCT06544343Not applicable
- A Study of IMC-002 for the Treatment of Active Systemic Lupus ErythematosusRecruitingNCT06535412Phase 1/2
- A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus ErythematosusEnrolling by invitationNCT06518668Phase 1
- IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT06513429Not applicable
- Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus ErythematosusEnrolling by invitationNCT06475742Phase 3
- F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus ErythematosusNot yet recruitingNCT06468683Phase 1
- REACT-01: Reversing Autoimmunity Through Cell TherapyRecruitingNCT06465147Phase 1
- Neutrophil Extracellular Traps in Different Forms of Systemic SclerosisRecruitingNCT06462768
- Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)RecruitingNCT06458972
- Intervention to Improve Communication and Medication Adherence in LupusRecruitingNCT06458075Not applicable
- Neuropsycatric Disorders Among Children With Systemic Lupus Erythematosus in Sohag University HospitalRecruitingNCT06449794
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult SubjectsRecruitingNCT06448273Phase 1
- Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune DisordersRecruitingNCT06434363Phase 1/2
- Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune DiseasesRecruitingNCT06428188Phase 1/2
- Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus ErythematosusRecruitingNCT06421701Phase 1
- The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT06420154Early Phase 1
- Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT06417398Early Phase 1
- Deep Phenotyping of Cutaneous Lupus ErythematosusRecruitingNCT06411106Not applicable
- The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Ratio in Systemic Lupus Erythematosus PatientsNot yet recruitingNCT06404723
- Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus ErythematosusRecruitingNCT06400537Phase 1
- Efficacy and Safety of Telitacicept for Prevention of Flares in SLE PatientsRecruitingNCT06394063Not applicable
- An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune DiseaseRecruitingNCT06379646Not applicable
- Electroencephalogram Recording in Patients With Systemic Lupus ErythematosusRecruitingNCT06378736
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune DiseaseEnrolling by invitationNCT06375993Phase 1
- A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus ErythematosusNot yet recruitingNCT06373991Phase 1
- Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune DiseaseRecruitingNCT06373081Not applicable
- Systemic Lupus Erythematosus and Chlordecone Impregnation in MartiniqueRecruitingNCT06365359
- Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesRecruitingNCT06361745Not applicable
- A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus ErythematosusNot yet recruitingNCT06360068Phase 2
- Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus ErythematosusNot yet recruitingNCT06356740Phase 2
- Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)RecruitingNCT06350110Phase 1/2
- CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus ErythematosusRecruitingNCT06349343Phase 1
- CAR-T Cells in Systemic B Cell Mediated Autoimmune DiseaseRecruitingNCT06347718Phase 1/2
- BAFF CAR-T Cells (LMY-920) for Systemic Lupus ErythematosusRecruitingNCT06340750Phase 1
- A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)Not yet recruitingNCT06340490Phase 1
- Belimumab in SLE Synovial Inflammation and Lymph NodesRecruitingNCT06327724
- Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune DiseasesRecruitingNCT06316791Early Phase 1
- Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune DiseasesRecruitingNCT06316076Phase 1
- INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World UseRecruitingNCT06314282
- The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus PatientsRecruitingNCT06313151
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseaseRecruitingNCT06308978Phase 1
- Fatigue in Lupus Intervention Programmes (FLIP)RecruitingNCT06308770Not applicable
- Relma-cel for Moderate to Severe Active Systemic Lupus ErythematosusNot yet recruitingNCT06297408Phase 1
- Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.Enrolling by invitationNCT06294483
- Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus PatientsNot yet recruitingNCT06287125